The C360 line “is key to our long-term strategy and represents a significant opportunity for growth,” said Massimo Calafiore, executive vice president of global business units at NuVasive.
NuVasive also launched the Anterior Cervical Plating system, which aims to reduce post-op complications such as dysphagia, malalignment and adjacent level ossification.
The C360 portfolio also includes Reline Cervical, a posterior fixation system expected to be commercially available in 2021.
More articles on devices:
Dr. Daniel Lieberman: How hospitals will react to outpatient migration & what’s next for spine at ASCs
Illinois Bone & Joint Institute CEO on M&As in 2020 and future strategy
Nick Saban lauds orthopedic surgeon named as SEC Team Physician of the Year
